Related Experiment Videos

Bisphosphonate therapy in children with secondary osteoporosis

Socrates E Papapoulos1

  • 1Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands. S.E.Papapoulos@lumc.nl

Hormone Research in Paediatrics
|July 23, 2011
PubMed

Insights

Bisphosphonates are used for pediatric secondary osteoporosis, but evidence doesn't support standard use. Their application should be limited to children with fragility fractures and low bone mass.

Area of Science:

  • Pediatric Endocrinology
  • Pharmacology
  • Bone Metabolism

Background:

  • Secondary osteoporosis in children is linked to chronic conditions, causing bone fragility.
  • Bisphosphonates, effective in adult osteoporosis, are explored for pediatric use.
  • Extrapolation of adult bisphosphonate data to children is limited due to differing disease progression and pharmacokinetics.

Discussion:

  • Current evidence on bisphosphonate use in pediatric secondary osteoporosis is insufficient for routine recommendation.
  • The efficacy and safety profile in children require further investigation.
  • Clinical decision-making must consider the specific pediatric context.

Key Insights:

  • Bisphosphonates show potential but are not yet standard therapy for pediatric secondary osteoporosis.
  • Treatment decisions should be individualized based on fracture risk and bone mineral density.
  • Further research is crucial to establish optimal pediatric protocols.

Outlook:

  • Future studies should focus on pediatric-specific dosing, long-term outcomes, and safety.
  • Bisphosphonates may become a more established option for specific pediatric populations with further evidence.
  • Understanding pharmacokinetic and pharmacodynamic differences is key for future therapeutic development.
Abstract

Related Concept Videos

Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...